Dashboard
Manage Tickers

ARTL ARTELO BIOSCIENCES, INC.

Nasdaq artelobio.com


$ 4.25 $ 0.25 (6.02 %)    

Wednesday, 15-Oct-2025 12:13:37 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.59 $ -1.24 (-0.21 %)
DIA $ 463.47 $ -1.21 (-0.26 %)
SPY $ 665.01 $ -1.76 (-0.26 %)
TLT $ 90.68 $ -0.27 (-0.3 %)
GLD $ 385.73 $ -0.23 (-0.06 %)
$ 4.14
$ 4.15
$ 4.22 x 12
$ 4.28 x 10
$ 4.23 - $ 4.47
$ 4.00 - $ 28.60
112,747
na
5.47M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-25-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 01-12-2022 11-30-2021 10-Q
16 11-29-2021 08-31-2021 10-K
17 07-12-2021 05-31-2021 10-Q
18 04-13-2021 02-28-2021 10-Q
19 01-14-2021 11-30-2020 10-Q
20 11-04-2020 08-31-2020 10-K
21 07-13-2020 05-31-2020 10-Q
22 04-13-2020 02-29-2020 10-Q
23 01-14-2020 11-30-2019 10-Q
24 11-25-2019 08-31-2019 10-K
25 07-15-2019 05-31-2019 10-Q
26 04-15-2019 02-28-2019 10-Q
27 01-14-2019 11-30-2018 10-Q
28 11-29-2018 08-31-2018 10-K
29 07-13-2018 05-31-2018 10-Q
30 04-16-2018 02-28-2018 10-Q
31 01-16-2018 11-30-2017 10-Q
32 11-29-2017 08-31-2017 10-K
33 07-21-2017 05-31-2017 10-Q
34 04-14-2017 02-28-2017 10-Q
35 01-10-2017 11-30-2016 10-Q
36 11-29-2016 08-31-2016 10-K
37 07-05-2016 05-31-2016 10-Q
38 04-01-2016 02-29-2016 10-Q
39 01-14-2016 11-30-2015 10-Q
40 12-11-2015 08-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

artelo-biosciences-reports-phase-1-and-2-data-for-art2612-and-art2713-highlighting-safety-and-significant-weight-gain-in-cancer-anorexia-trial
Artelo Biosciences Reports Phase 1 And 2 D...
10/15/2025 13:18:39

ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed...

artelo-biosciences-prices-20m-public-offering
Artelo Biosciences Prices $2.0M Public Off...
09/30/2025 14:11:59

SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutic...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 12:09:34

why-wolfspeed-shares-are-trading-higher-by-over-50-here-are-20-stocks-moving-premarket
Why Wolfspeed Shares Are Trading Higher By...
09/30/2025 09:37:13

reported-earlier-artelo-biosciences-commences-underwritten-public-offering-of-common-stock-and-pre-funded-warrants
Reported Earlier, Artelo Biosciences Comme...
09/30/2025 06:34:00

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
09/19/2025 12:09:04

artelo-biosciences-announces-publication-of-new-preclinical-data-on-art1211-proprietary-cannabidioltetramethylpyrazine-cocrystal
Artelo Biosciences Announces Publication O...
09/10/2025 12:36:52

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...

this-science-applications-international-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-monday
This Science Applications International An...
09/08/2025 13:35:13

d-boral-capital-downgrades-artelo-biosciences-to-hold
D. Boral Capital Downgrades Artelo Bioscie...
09/08/2025 11:21:26

D. Boral Capital analyst Jason Kolbert downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.

nasdaq-gains-over-100-points-science-applications-shares-fall-after-q2-results
Nasdaq Gains Over 100 Points; Science Appl...
09/04/2025 19:06:34

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 17:05:59

dow-surges-200-points-us-initial-jobless-claims-rise
Dow Surges 200 Points; US Initial Jobless ...
09/04/2025 16:37:17

artelo-biosciences-prices-640924-share-offering-at-440share-and-pre-funded-warrants-at-4399-proceeds-3m
Artelo Biosciences Prices 640,924 Share Of...
09/04/2025 12:40:23

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 12:08:12

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/03/2025 21:06:23

artelo-biosciences-announces-proposed-underwritten-public-offering-of-common-stock-andor-pre-funded-warrants-size-not-disclosed
Artelo Biosciences Announces Proposed Unde...
09/03/2025 20:38:20

artelo-biosciences-drug-helps-cancer-patients-regain-weight-eyes-licensing-deal
Artelo Biosciences Drug Helps Cancer Patie...
09/03/2025 17:45:42

Artelo Biosciences reported encouraging Phase 2 trial results for ART27.13 in cancer anorexia-cachexia syndrome, citing strong ...

artelo-biosciences-announces-interim-results-from-phase-2-cares-trial-with-art2713-peripherally-acting-cannabinoid-receptor-agonist-for-treatment-of-cacs
Artelo Biosciences Announces Interim Resul...
09/03/2025 12:47:46

Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACSConsistent Im...

d-boral-capital-maintains-buy-on-artelo-biosciences-maintains-18-price-target
D. Boral Capital Maintains Buy on Artelo B...
08/26/2025 11:55:01

D. Boral Capital analyst Jason Kolbert maintains Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $18 price target.

artelo-biosciences-announced-results-from-its-preliminary-food-effect-evaluation-with-art2612-as-a-part-of-the-single-ascending-dose-phase-1-trial-for-persistent-pain
Artelo Biosciences Announced Results From ...
08/25/2025 11:57:59

Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted ConditionsCompletion of Positive Single Ascending D...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION